BACKGROUND INFORMATION ON THE PROCEDURE 
1 
Submission of the dossier 
The  applicant  Schein  Pharmaceuticals  UK  Ltd  submitted  on  6  December  2002  an  application  for 
Marketing Authorisation to the European Agency for the Evaluation of Medicinal Products (EMEA) 
for  Oxybutynin  Nicobrand,  in  accordance  with  the  centralised  procedure  falling  within  the  scope  of 
Part  B  of  the  Annex  to  Council  Regulation  No  (EEC)  2309/93  of  22  July  1993,  as  amended.  
On  9  September  2003  the  EMEA  was  informed  of  a  name  change  of  the  applicant  from  Schein 
Pharmaceutical UK Ltd to Nicobrand Limited. 
The Rapporteur and Co-Rapporteur appointed by the CPMP were: 
Rapporteur:  Dr. Pieter Neels   
Co-Rapporteur: 
Prof. Cristina Sampaio 
Scientific Advice: 
The applicant did not seek scientific advice from the CPMP. 
Licensing status: 
Oxybutynin Nicobrand has been given a Marketing Authorisation in the USA on 03/03/2003. A new 
application is pending in Canada. 
2 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
Steps taken for the assessment of the product 
The procedure started on 24 February 2003. 
The Rapporteur's first Assessment Report was circulated to all CPMP members on 9 May 2003. 
The  Co-Rapporteur's  first  Assessment  Report  was  circulated  to  all  CPMP  members  on 
6 May 2003. 
During the meeting on 26 June 2003, the CPMP agreed on the consolidated List of Questions to 
be sent to the applicant. 
The  summary  report  of  the  inspection  carried  out  at  the  manufacturing  site  of  the  finished 
product  Watson  Laboratories,  Inc,  Salt  Lake  City,  Utah,  USA,  between  29-31  July  2003  was 
issued on 17 October 2003 
The  applicant  submitted  the  responses  to  the  CPMP  consolidated  List  of  Questions  on 
9 September 2003. 
The Rapporteurs circulated the Joint Assessment Report on the applicant’s responses to the List 
of Questions to all CPMP members on  24 October 2003. 
Further to clarificatiom received from the Applicant on 11 November 2003, the Rapporteur and 
Co-rapporteur circulated an addendum to the Joint Assessment Report on 14 November 2003. 
During the meeting on 20 November 2003, the CPMP, in the light of the overall data submitted 
and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for  granting  a 
Marketing Authorisation to Oxybutynin Nicobrand on 20 November 2003.  
The  European  Commission  requested  to  reconsider  this  application  according  to  a  different 
legal basis and subsequently to revise the initial Opinion of 20 November 2003. 
During  the  meeting  on  24-26  February  2004  the  CPMP,  in  the  light  of  the  overall  data  and 
justifications  submitted  and  the  scientific  discussion  within  the  Committee,  issued  a  revised 
positive  Opinion  for  granting  a  Marketing  Authorisation  to  Oxybutynin  Nicobrand  on 
26 February 2004. 
1/1 
EMEA 2004 
 
 
 
 
 
